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SUMMARY COPD very often coexist with comorbidities, usually sharing the same risk factors and negatively influencing other diseases. COPD 
and comorbidities are caused and worsened by inflammatory and oxidative mechanisms with prevalence ranging from 20% to 81%. Cardiovascular 
diseases (CD) have the highest incidence and potentially the highest risk of death, taking into account other comorbidities. Common pathophysiological 
mechanisms are endothelial dysfunction, pro-coagulant and pro-inflammatory conditions and obesity. The most common cardiovascular comorbidities 
are coronary heart disease, heart failure, arterial hypertension and peripheral vascular disease. Reduction in FEV1 increases the rate of coronary events 
and mortality. Timely diagnosis of CD in COPD patients is necessary, as well as making diagnosis of COPD in patients with CD. Invasive and noninvasive 
assessment of CHD is often difficult in COPD patients because they exhibit respiratory limitations during exercise and stress. Arterial hypertension and 
peripheral vascular disease occur frequently in COPD patients due to endothelial dysfunction. Pulmonary function is negatively correlated with blood 
pressure in a healthy population and COPD patients. The prevalence of heart rhythm disorders is 12%– 14% in COPD patients and atrial fibrillation is 
the most common among them. Inhaled long-acting beta-2-agonists have an acceptable safety profile in cardiovascular patients. Osteoporosis is the 
major COPD comorbidity, which is often under-diagnosed and correlated with poor overall health status and COPD prognosis. Vitamin D deficiency 
relates to COPD and its comorbidities reducing innate and acquired immunity. Lung cancer, metabolic syndrome, obesity, malnutrition, depression, 
obstructive sleep apnea, muscle dysfunction and anemia are COPD comorbidities as well.
KEY WORDS: COPD, comorbidity, cardiovascular diseases, osteoporosis, vitamin D deficiency, obesity, lung cancer, depression
SAŽETAK KOPB je često udružen s komorbiditetima s kojima dijeli iste rizične faktore i ima negativan utjecaj na druge bolesti. KOPB i 
njegove komorbiditete uzrokuje i pogoršava upala i mehanizam oksidacije u rasponu od 20 do 81 %. Najveću incidenciju i najveći smrtni rizik nose 
kardiovaskularne bolesti. Uobičajeni patofiziološki mehanizam je endotelna disfunkcija, prokoagulantno i proinflamatorno stanje te pretilost. Najčešći 
kardiovaskularni komorbiditeti su koronarna bolest srca, srčano zatajivanje, arterijska hipertenzija i periferna vaskularna bolest. Smanjenje FEV1 
povećava učestalost koronarnih događaja i mortalitet. U bolesnika s KOPB-om neophodna je pravovremena dijagnoza kardiovaskularne bolesti kao i 
dijagnoza KOPB-a u kardiovaskularnih bolesnika. Invazivna i neinvazivna procjena kroničkoga srčanog zatajivanja je otežana u bolesnika s KOPB-om 
jer bolesnik može imati ograničenja respiracije za vrijeme vježbanja i stresa. Arterijska hipertenzija i periferna vaskularna bolest su česte u bolesnika 
s KOPB-om zbog endotelne disfunkcije. Funkcija pluća je negativno povezana s krvnim tlakom i u zdravoj populaciji i kod bolesnika s KOPB-om. U 
bolesnika s KOPB-om prevalencija poremećaja srčanog ritma iznosi 12 do 14 %, a među njima je najčešća fibrilacija atrija. Inhalacija dugodjelujućeg beta 
2 agonista ima prihvatljivu podnošljivost kod kardiovaskularnih bolesnika. Osteoporoza je glavni komorbiditet kod bolesnika s KOPB-om, ali je često 
nedovoljno dijagnosticirana i povezana s cjelokupno lošim zdravstvenim statusom i prognozom KOPB-a. Nedostatak vitamina D povezan je s KOPB-om 
i komorbiditetima koji smanjuju urođeni i stečeni imunitet. Karcinom pluća, metabolički sindrom, pretilost, malnutricija, depresija, opstruktivna apneja 
za vrijeme spavanja, disfunkcija mišića i anemija također su komorbiditeti KOPB-a.
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Chronic Obstructive Pulmonary 
Disease and Comorbidities
COPD very often coexist with other diseases, and 
comorbidities in COPD are the rule, rather than 
exception. These conditions usually share the same 
risk factors (smoking cigarettes, indoor and outdoor air 
pollution, etc.) and may have a negative influence to other 
disease. The prevalence of COPD comorbidities in COPD 
patients ranges from 20% to 81% (1, 2). The importance of 
the relationship between COPD and comorbidities is well 
recognized nowadays and reported in Chapter 6 in the 
Global Initiative for COPD (2). 
Comorbid diseases are present in all GOLD stages, 
influenced and worsened not only by the inflammatory 
and oxidative mechanism in COPD, but also by COPD 
sequelae (impaired physical activity, active smoking, 
anxiety and depression, etc.). Some comorbid diseases with 
symptoms suggesting COPD may be overlooked (e.g. heart 
failure, lung cancer, infection, depression). Therefore, the 
treatment approach to a COPD patient must include not 
only the treatment of comorbid disease but the disease 
identification as well. 
p
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Pathogenic mechanisms in COPD 
comorbidities
COPD and comorbidities are caused and worsened by the 
inflammatory mechanism and imbalance in oxidative/anti-
oxidative mechanisms. The chronic inflammation in lungs 
is caused by pro-inflammatory mediators and oxidative 
stress. The pro-inflammatory mediators are produced 
and secreted not only by inflammatory cells recruited 
from the circulation (alveolar macrophages, neutrophils, 
T-lymphocytes), but also by structural cells (epithelial cells, 
endothelial cells, fibroblasts) (3). Oxidative stress is increased 
in these patients and may activate the nuclear factor-kB, 
impair anti-proteases’ roles, autoantibodies production, 
resistance to corticosteroids and DNA damage. Systemic 
inflammation contributes and worsens comorbidities 
(cardiovascular diseases, osteoporosis, diabetes, etc.). 
Therefore, the treatment of lung inflammation by inhaled 
or systemic anti-inflammatory therapies also has favorable 
effects on COPD and its comorbidities. 
Cardiovascular diseases
Cardiovascular associated diseases have the highest 
incidence and potentially the highest risk of death, taking 
into account other comorbidities. The reason is common 
pathophysiological mechanisms caused by endothelial 
dysfunction (4), pro-coagulant (5) and pro-inflammatory 
conditions, and obesity with high Body Mass Index (BMI) 
(6), but also common risk factors such as smoking. The 
most common cardiovascular comorbidities in COPD 
patients: coronary heart disease, heart failure, arterial 
hypertension and peripheral vascular disease. Mortality in 
COPD due to cardiovascular cause occurs in 12% to 37% in 
various studies (7).
Coronary heart disease
Reduction in FEV1 by 10% increases the rate of non-
fatal coronary events by 20% and mortality by 28% (8). 
The presence of three-vessel disease and lower FEV1 
were independently associated with survival rates from 
COPD (9). Symptoms related to myocardial ischemia 
(pressure and chest pain, dyspnea on exertion) may also be 
present in COPD patients. In addition, the triggers for the 
manifestation and symptoms exacerbation are the same 
(physical effort, stress, exposure to cold). McAlister studied 
the history of chest pain in patients hospitalized for COPD 
exacerbation and noted that 51% had chest pain and 40% 
had pain whose characteristics were highly suspicious for 
myocardial ischemia (10). 
Therefore, timely diagnosis of CD in patients with COPD 
is necessary, as well as diagnosing COPD in patients with 
CD. However, noninvasive assessment of coronary heart 
disease is difficult in COPD patients because they often 
exhibit respiratory limitations during exercise. Therefore, 
stress tests often cannot be performed or cannot shows 
beneficial results, and a pharmacological stress test can 
lead to pronounced bronchospasm. Echocardiography 
often cannot validly assess the condition in patients with 
COPD due to hyperinflation and technical limitations (11). 
More recently, scanning (MSCT) coronary angiography has 
been used to assess stable CD, and coronary angiography 
has a medical justification for performing it more frequently 
in these patients. Some studies have shown that arterial 
stiffness and rigidity associated with COPD may be due in 
part to increased arterial calcification that also correlates 
with emphysema severity. 
Heart failure
COPD and heart failure (HF) are conditions that often 
coexist in the same patient, with a prevalence of COPD in 
20% to 30% of patients with HF (12). COPD is one of three 
major comorbidities that have an effect on quality of life 
and outcome of patients with heart failure with reduced 
ejection fraction (13). Unrecognized HF was diagnosed in 
20.5% of COPD patients treated in primary practice (14). In 
the ECLIPSE study, the prevalence of HF in patients with 
moderate to severe COPD was 7% (15). 
In addition, COPD is a significant predictor of poor 
prognosis in patients with HF. Physical inactivity and 
metabolic syndrome are conditions that cause HF in the 
general population, and therefore contribute to HF in COPD 
patients. COPD is a predictor of mortality in HF, and FEV1 
is an independent predictor of all-cause death in patients 
hospitalized for HF (16, 17). Markers of myocardial injury 
are used not only to diagnose myocardial injury but also 
to indicate left ventricular dysfunction in finding the 
etiology differentiate dyspnea. NT pro-BNP is a biomarker 
associated with increased mortality in stable and acute 
heart disease, but also a predictor of mortality 30 days after 
hospitalization due to COPD exacerbation.
Arterial hypertension
Arterial hypertension (AT) and peripheral vascular disease 
(PVD) occur frequently in COPD patients due to endothelial 
dysfunction caused by inflammatory mediators and 
oxidative stress. Pulmonary function is negatively correlated 
with blood pressure in a healthy population and in patients 
with COPD. The prevalence of heart rhythm disorders is 12% 
to 14% in patients with COPD, and atrial fibrillation (AF) 
is the most common among them. AF is more common in 
patients with a more severe form of the disease and more 
pronounced bronchial obstruction.
The management of patients with COPD and cardiovascular 
comorbidities is complex. Drug treatment strategy for 
patients with COPD and cardiovascular comorbidities is 
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based on COPD therapy consistent with disease severity, 
but also on cardio selective beta-blockers, angiotensin-
converting enzyme inhibitors, angiotensin receptor 
blockers, or antiplatelet agents. Long-acting beta-2-
agonists have an acceptable safety profile in cardiovascular 
patients. 
COPD and osteoporosis
Osteoporosis is the major COPD comorbidity which is often 
under-diagnosed and correlated with poor overall health 
status and COPD prognosis. Several studies have examined 
the status of vitamin D in COPD patients. Forli et al. have 
reported the presence of severe deficiency (vitamin D 
concentrations were lower than 20 μg/L) in patients with the 
terminal stage of chronic lung disease who were awaiting 
transplantation (18).
Belgian authors clearly showed the positive correlation 
between vitamin D concentration and FEV1. Significantly 
higher vitamin D concentration was also observed in healthy 
smokers compared to COPD patients who are smokers (19). 
Vitamin D concentration decreases with COPD progression 
and this difference becomes higher. After classification of 
patients according to GOLD stage, a significant difference 
is noticeable already in GOLD 2 stage. Patients in stage IV 
had the lowest concentration of vitamin D. The results of an 
American study performed on more than 14,000 American 
citizens older than 20 years suggest that people with oxygen 
saturation over 88% have significantly higher blood vitamin 
D concentrations (20).
The causes of vitamin D deficiency in the general population 
and COPD patients have been studied in various studies. 
Some of the most important findings so far could be: 
insufficient sun exposure, decreased synthesis of vitamin 
D precursors in the skin, vitamin malabsorption in the 
gastrointestinal tract, obesity and type II diabetes, obesity, 
older age, deficient food intake, inadequate activation in the 
liver and sequestration in adipose tissue. These underlined 
causes dominate in COPD patients. 
It is well known that bone formation and resorption are 
related to the close interaction of osteoblasts and osteoclasts. 
Osteoblasts constitutively express on their surface a ligand 
for a nuclear factor receptor activator ƙB (RANK-L). They 
differentiate into mature active osteoclasts when this ligand 
binds to its receptor on pre-osteoclast cells. Osteoblasts 
secrete osteoprotegerin that blocks the RANK/RANK-L 
interaction and regulates bone turnover. The imbalance 
between OPG and RANK-L increases osteoclast activity 
and it is thought to be one of the major mechanisms in 
the pathogenesis of osteoporosis. Systemic inflammation, 
corticosteroid use and lower vitamin D levels contribute to 
this imbalance. Therefore, the vitamin D supplementation 
with 700-800 IU/day is recommended for COPD patients 
while ensuring adequate calcium intake (1000 mg/day). 
This supplementation should not start before determining 
the patient’s vitamin D status (21).
How does vitamin D deficiency relate to COPD 
comorbidities? Vitamin D activates innate immunity and 
suppresses acquired immunity, stimulates the synthesis 
of antimicrobial peptides cathelicidin and beta-defensins. 
it thus limits the inflammation and infection, which 
are the first steps in COPD pathogenesis. Therefore, the 
vitamin also controls the systemic comorbidities of COPD: 
cardiovascular diseases, lung cancer, myopathy, diabetes 
and osteoporosis.
Vitamin D also has a positive effect on COPD comorbidities 
such as skeletal muscle weakness, cardiovascular disease 
and cancer. Conventional therapy cannot stop the COPD 
progression, so it is necessary to investigate the wider 
potential of the vitamin’s pleotropic effects and to define 
the optimal blood concentrations of 25 (OH) D. 
Lung cancer
COPD and lung cancer are strongly associated and coexist in 
a large number of patients. Smoking remains the main risk 
factor for both COPD and lung cancer.  
Van Den Eeden and Friedman are the first authors who 
studied the relationship between FEV1 and lung cancer 
among smokers and never-smokers (22). Proportional 
hazards models revealed a decreasing trend in risk of 
lung cancer incidence with increasing FEV1 in current and 
former smokers. This negative relationship between FEV1 
and lung cancer was analyzed in meta-analysis published 
by Zhang X. et al. (23). De Torres et al. reported the incidence 
of 8.5 % in patients with lung cancer in COPD, with higher 
incidence (83.8%) in patients older than 64 years (24). Over 
half (51%) had at least one comorbid condition and 43% 
had chronic lung disease. Distinct comorbidity profiles are 
independent predictors of treatment and survival. Lung 
emphysema is an important independent risk factor for 
lung cancer (25).
Lung cancer should be treated as usual, regardless of the 
existence of COPD, and COPD should be treated according 
to actual guidelines. A multidisciplinary approach is the 
best way to choose the optimal management for patients 
with lung cancer and impaired lung function due to 
COPD. 
COPD and other comorbidities
Depression, metabolic syndrome and diabetes, obesity, 
malnutrition, depression, obstructive sleep apnea, 
skeletal muscle dysfunction and anemia are also COPD 
comorbidities. These diseases are caused by inflammatory 
mechanisms, and associated with poorer quality of 
life, worse prognosis and high risk for multi-morbidity. 
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They should be carefully examined and treated as usual, 
regardless of the existence of COPD, and COPD should be 
treated according to COPD guidelines with a multimodality 
care plan. 
Conclusion
COPD very often coexist with comorbidities, usually sharing 
the same risk factors and negative influencing to other 
disease. The prevalence of COPD comorbidities ranges from 
20% to 81% and most often they are cardiovascular diseases, 
osteoporosis, lung cancer, depression, metabolic syndrome, 
obesity, malnutrition, obstructive sleep apnea and anemia. 
They should be carefully examined and treated as usual, 
regardless of the existence of COPD, and COPD should be 
treated according to COPD guidelines. 
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